SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today ...

Myriad Genetics, Inc. MYGN announced that its Vectra test was included by the American College of Rheumatology (“ACR”) in its list of recommended disease activity measures for patients with rheumatoid ...

Sample test report for Vectra CV. Sample test report for Vectra CV. SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc.

New data has demonstrated an association between high Vectra DA scores and an increased risk of joint damage progression in patients with rheumatoid arthritis. On Wednesday at the European League ...

While the emergence of new antirheumatic agents—including biologics—has revolutionized the treatment of rheumatoid arthritis (RA), these drugs come a high cost to the healthcare system.

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new ...

Please provide your email address to receive an email when new articles are posted on . The Vectra multi-biomarker disease score, as determined by the Vectra molecular blood test, is a more successful ...

Myriad Genetics, Inc. MYGN is in the process of presenting favorable data related to the Vectra test, as part of its Autoimmune business, at the on-going 2019 ACR/ARP Annual Meeting in Atlanta, GA.

SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data ...

SALT LAKE CITY, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra ® that evaluated ...